Skip to content

Pharminent

cropped-banner_frontpage_2026-07-11-2.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Clinical Data
  • AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data
  • Clinical Data

AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data

BioSpace

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses at head and neck cancer.

Clinical DataRead full story

pharminent April 21, 2026 (Last updated: April 21, 2026)

BioSpace

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses at head and neck cancer.

Clinical DataRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: MSD, Eisai report setback in first-line kidney cancer trial
Next: Novo Nordisk preps filings for sickle cell drug etavopivat

Related Stories

  • Clinical Data

AstraZeneca, Ionis drug fails big heart disease study in major setback

pharminent July 9, 2026
  • Clinical Data

Roche’s KRAS drug tops its rivals in lung cancer trial

pharminent July 2, 2026
  • Clinical Data

EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s

pharminent July 1, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.